Last updated: June 3, 2026
ALLEGRA-D 12 Hour Allergy and Congestion market dynamics, pricing, and financial trajectory (US)
ALLEGRA-D 12 Hour (fexofenadine hydrochloride 60 mg and pseudoephedrine hydrochloride 120 mg extended-release tablets) has limited patent-driven supply-side differentiation and trades as a mature branded OTC product with broad generic competition. Market growth is constrained by (1) OTC demand maturity, (2) pull-through from seasonality, and (3) dispensing and regulatory friction associated with pseudoephedrine. Financial performance tracks retail velocity and promo intensity rather than product innovation, with margin pressure from generic shelf incumbents and private label.
What are ALLEGRA-D 12 Hour’s market dynamics in the US OTC allergy and congestion category?
Category structure. ALLEGRA-D 12 Hour sits at the intersection of oral second-generation antihistamines (fexofenadine) and decongestants (pseudoephedrine). In the US OTC channel, the category is split between:
- Antihistamine-only (e.g., fexofenadine, loratadine, cetirizine)
- Antihistamine-decongestant combinations (pseudoephedrine-based, plus phenylephrine-based alternatives)
- Nasal therapies (steroids, antihistamine sprays)
- Syrups and chewables (demographics and compliance-driven)
Demand drivers.
- Seasonality: Retail sales peak during spring and fall allergy windows, with congestion severity and pollen intensity influencing demand more than drug “brand switching.”
- Workforce and travel usage: Congestion relief expectations support stronger conversion to combination products versus antihistamine-only in periods of high congestion.
- Safety/eligibility constraints: Pseudoephedrine availability and patient eligibility (cardiovascular contraindications, sensitivity, age limitations) reduce the addressable pool versus antihistamine-only.
Supply and competitive dynamics.
- Generic density: Combination tablets containing fexofenadine plus pseudoephedrine have generic equivalents and wide retailer sourcing. Brand differentiation is largely marketing, pack configuration, and trade terms rather than exclusivity.
- Substitution pressure: Consumers and pharmacists substitute across:
- fexofenadine-pseudoephedrine to other antihistamine-decongestant choices
- pseudoephedrine to phenylephrine-containing products (with lower efficacy expectations in practice)
- oral combinations to intranasal corticosteroids for persistent congestion
How does pseudoephedrine regulation affect ALLEGRA-D 12 Hour sales?
Pseudoephedrine OTC products are constrained by US retail compliance regimes (sales behind-the-counter, age limits, ID requirements, and sales logging rules under Combat Methamphetamine Epidemic Act controls). That raises:
- friction at the point of sale versus non-pseudoephedrine OTCs
- transaction time and customer drop-off risk during peak demand
- retailer compliance costs
In periods of high traffic, this can shift share toward non-pseudoephedrine options unless consumers specifically seek congestion relief from pseudoephedrine.
Which competitive OTC routes erode ALLEGRA-D’s shelf share?
- Other antihistamine-decongestant combos: comparable dosing convenience and retailer preference for non-branded SKUs.
- Nasal steroid sprays: high adherence for chronic rhinitis and congestion, reducing demand for oral decongestant combinations.
- Chewables and rapid gels: compliance advantages in households with children.
When does ALLEGRA-D 12 Hour lose exclusivity and why does that matter commercially?
ALLEGRA-D 12 Hour is a legacy combination product. Its commercial trajectory is dominated by the shift from brand exclusivity to generic and private-label interchangeability. The practical effect: once key branded exclusivity barriers fall, retailers gain leverage to demand lower net pricing and to steer toward generics or store brands.
Featured snippet answer: ALLEGRA-D 12 Hour’s long-term sales are not driven by exclusivity tailwinds; they track OTC seasonality and generic substitution after exclusivity erosion.
What is the patent estate reality for combination products like ALLEGRA-D 12 Hour?
Combination brands in OTC allergy are typically protected by a mix of:
- API composition or salt-related claims (often long expired for established actives)
- formulation and dosage form claims for extended-release behavior
- method-of-use and manufacturing claims
- later-life lifecycle claims that may or may not block generics
Commercially, even when some formulation patents exist, generic entry tends to occur when:
- regulatory bioequivalence pathways permit formulation substitution
- residual patents do not block ANDA labeling that matches therapeutic category expectations
- OTC channel prefers price leadership
How strong is the patent estate for ALLEGRA-D 12 Hour versus generic risk?
For mature OTC combination products, generic risk is high because:
- the actives are well-established
- extended-release technology is widely understood
- retail demand is price-sensitive
Featured snippet answer: Generic substitution risk is structurally elevated, so brand profitability depends mainly on net pricing, promotions, and retailer contracts rather than patent term.
What generic entry risks exist for fexofenadine-pseudoephedrine 12-hour formulations?
Key barriers generics face are usually not regulatory feasibility of combining two well-known actives, but instead:
- proving acceptable bioequivalence for extended-release behavior
- avoiding patent claims if still in force on specific extended-release formulations or release profiles
- meeting OTC labeling and pseudoephedrine compliance requirements
What is the Orange Book status of ALLEGRA-D 12 Hour?
ALLEGRA-D 12 Hour is an OTC product that is regulated and marketed in the US; its exclusivity and patent listings, where applicable, would be reflected in the FDA Orange Book for each specific drug product and strength.
No Orange Book listings were provided in the prompt, so no accurate Orange Book mapping can be produced here without risking factual error.
What formulations and dosage strengths define ALLEGRA-D 12 Hour’s commercial footprint?
ALLEGRA-D 12 Hour is defined by:
- fexofenadine hydrochloride 60 mg
- pseudoephedrine hydrochloride 120 mg
- extended-release tablet format
- “12 hour” consumer positioning for convenient dosing and congestion coverage
Economic implication: Extended-release positioning can improve conversion rates versus shorter-interval decongestant regimens, but it does not protect against generic substitution if bioequivalence and patent status permit.
How does ALLEGRA-D 12 Hour compare with competing OTC allergy and congestion products financially?
In OTC, financial outcomes depend on:
- gross-to-net erosion from promotions
- trade spend and retailer fees
- brand-to-generic switching frequency
ALLEGRA-D’s competitive benchmark set typically includes:
- other antihistamine-decongestant combos (pseudoephedrine-based or phenylephrine-based)
- antihistamines without decongestant (better compliance and simpler purchase experience)
- nasal steroid sprays for congestion-driven users
Working market logic: ALLEGRA-D tends to hold share best when consumers strongly prefer pseudoephedrine-driven congestion relief and value extended-release convenience. In high price sensitivity periods, generics and private label take more share.
What market share and revenue trajectory should investors expect for ALLEGRA-D 12 Hour?
A full revenue model requires syndicated retail data and company-level segment disclosures, which are not included in the prompt. What can be stated structurally for a mature OTC combination:
- Growth: tied primarily to seasonal peaks and demographic penetration, not innovation.
- Margins: compress over time as generics expand, leading to net price pressure.
- Volume: may stabilize even when net pricing declines, depending on promo intensity and category substitution dynamics.
- Volatility: higher in spring/fall due to pollen-year variability and weather.
How do promotions, channel strategy, and retailer contracting affect ALLEGRA-D 12 Hour profitability?
OTC branded combinations typically manage financial performance through:
- trade allowances and cooperative advertising
- slotting and endcap placement during peak allergy windows
- multibuy promotions
- contract pricing shifts when generics deepen
As generic penetration increases, the brand must increase promotional intensity to defend share. That raises marketing spend and reduces realized gross margin, shifting profitability to “net revenue management” rather than unit growth.
Key financial trajectory patterns for mature branded OTC allergy combinations like ALLEGRA-D
The typical trajectory profile in the US:
- Brand launch and early adoption: higher net price, lower generic share
- Generic entry and widening price gaps: share shifts to lower-cost SKUs
- Category maturity: volume stabilizes; seasonal peaks dominate
- Margin compression: persistent promo and trade needs
- Brand defense: packaging, convenience claims, and retailer relationships
ALLEGRA-D 12 Hour is aligned with stages 3 to 4, with the specific timing of generic share gains depending on product-specific competitive entries.
What litigation or settlements affect ALLEGRA-D 12 Hour competition?
No litigation dataset was provided in the prompt, so no accurate case mapping can be generated without inventing facts.
Does ALLEGRA-D 12 Hour face biosimilar or biologics-type exclusivity constraints?
No. ALLEGRA-D 12 Hour is a small-molecule OTC product, so biosimilar frameworks do not apply.
What are the most likely generic launch scenarios for ALLEGRA-D 12 Hour?
Given maturity and OTC interoperability, likely scenarios include:
- continued generic shelf replacement at major retailers
- private label and store-brand equivalents that undercut branded net pricing
- mix shift toward channels with higher price sensitivity
Commercially, branded outcomes then depend on maintaining acceptable net price through retailer contracting and limiting volume loss through effective consumer marketing.
How does ALLEGRA-D 12 Hour’s pricing typically evolve over time?
Absent specific historical net pricing data in the prompt, the direction is predictable for mature OTCs:
- list price may remain relatively stable
- net price falls via higher discounts, coupons, and trade promotions
- branded price gaps widen against generics, increasing substitution
What geographic considerations matter for ALLEGRA-D 12 Hour?
For US OTC products, the dominant geography is not regulatory coverage so much as:
- retailer footprint concentration
- state-level consumer behavior affecting pseudoephedrine compliance friction
- distribution agreements and distribution channel mix
Key Takeaways
- ALLEGRA-D 12 Hour is a mature OTC allergy and congestion combination defined by fexofenadine 60 mg and pseudoephedrine 120 mg extended-release tablets.
- Market dynamics are driven by seasonality and congestion intensity, with pseudoephedrine purchase friction limiting substitution against antihistamine-only options.
- Financial trajectory is primarily a gross-to-net and share-defence story under generic and private-label pressure, not an R&D innovation story.
- Patent exclusivity effects are secondary at this product stage; generic competition structurally constrains net pricing.
FAQs
1) What makes fexofenadine-pseudoephedrine combinations compete better than phenylephrine-only OTC decongestants?
Combination efficacy expectations tied to pseudoephedrine and dosing convenience drive consumer preference, but price sensitivity and compliance friction determine share in practice.
2) How do weather and pollen intensity impact ALLEGRA-D 12 Hour quarterly revenue?
They shift category volumes during spring and fall, increasing demand volatility and peak sales quarters.
3) Do coupons and retailer promos usually help branded ALLEGRA-D 12 Hour defend share against generics?
They can slow volume loss during peak season, but they also compress net margins.
4) What channel mix changes most affect ALLEGRA-D 12 Hour net pricing?
Shifts between mass retail, drugstore chains, and e-commerce typically change discount exposure and promotional intensity.
5) What labeling or purchasing constraints around pseudoephedrine can reduce conversion?
Behind-the-counter controls, ID checks, and sales logging requirements increase purchase friction versus non-pseudoephedrine products.
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Pseudoephedrine and retail sales restrictions under the Combat Methamphetamine Epidemic Act (CMEA). https://www.fda.gov/
